Lytix Biopharma AS

OB:LYTIX Stock Report

Market Cap: NOK 344.0m

Lytix Biopharma Valuation

Is LYTIX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LYTIX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LYTIX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LYTIX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LYTIX?

Key metric: As LYTIX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LYTIX. This is calculated by dividing LYTIX's market cap by their current revenue.
What is LYTIX's PS Ratio?
PS Ratio30.9x
SalesNOK 11.13m
Market CapNOK 344.04m

Price to Sales Ratio vs Peers

How does LYTIX's PS Ratio compare to its peers?

The above table shows the PS ratio for LYTIX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.7x
ABS Arctic Bioscience
3.4x35.6%NOK 109.1m
AZT ArcticZymes Technologies
8.5x15.1%NOK 919.3m
HBC Hofseth BioCare
3.6xn/aNOK 945.5m
PCIB PCI Biotech Holding
7.4xn/aNOK 49.8m
LYTIX Lytix Biopharma
30.9x47.2%NOK 344.0m

Price-To-Sales vs Peers: LYTIX is expensive based on its Price-To-Sales Ratio (30.9x) compared to the peer average (5.7x).

Price to Sales Ratio vs Industry

How does LYTIX's PS Ratio compare vs other companies in the European Biotechs Industry?

41 CompaniesPrice / SalesEstimated GrowthMarket Cap
LYTIX 30.9xIndustry Avg. 7.8xNo. of Companies41PS0816243240+
41 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: LYTIX is expensive based on its Price-To-Sales Ratio (30.9x) compared to the European Biotechs industry average (7.8x).

Price to Sales Ratio vs Fair Ratio

What is LYTIX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LYTIX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio30.9x
Fair PS Ratio11.5x

Price-To-Sales vs Fair Ratio: LYTIX is expensive based on its Price-To-Sales Ratio (30.9x) compared to the estimated Fair Price-To-Sales Ratio (11.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Price Target
Consensus Narrative from 1 Analyst
NOK 14.00
Fair Value
64.0% undervalued intrinsic discount
1
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/24 12:16
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lytix Biopharma AS is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carl RamaniusRedeye